SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ — Sirona Medical, a pioneer in cloud-native radiology workflow software solutions, announces the addition of nine new radiology practices to its Unify platform. Among them are Kansas Imaging Consultants, Radiologic Associates of Fredericksburg,…
Tag: SIRONA
Sirona Announces Support for SpaceX’s Starlink Network, Allowing Radiologists to Practice from Anywhere
SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ — Sirona Medical, the leader in cloud-native radiology workflow software, today announces general support for SpaceX’s Starlink platform, allowing Sirona’s industry-leading performance from almost anywhere in the world. “One of the biggest…
SIRONA completes enrollment – A leap in the DCB treatment of femoropopliteal arterial disease
TAMPA, Fla., Oct. 21, 2022 /PRNewswire/ — Concept Medical Inc. announces the successful completion of the SIRONA – World’s first and the largest head-to-head RCT investigating the use of Sirolimus Drug Coated Balloon (DCB) (Magic Touch PTA – Concept Medical Inc.) V/S Paclitaxel DCB angioplasty […]
Well Begun AND Half Done! – SIRONA Randomized Trial Achieves fifty percent enrollment
JENA, Germany, Feb. 9, 2022 /PRNewswire/ — Concept Medical Inc., focused on vascular intervention drug delivery devices, releases the second status update of SIRONA RCT (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in the Femoropopliteal Artery), as the trial completes half the targeted enrolment. SIRONA is […]
SIRONA – The world’s first and largest RCT comparing Sirolimus V/S Paclitaxel balloon for the treatment of Peripheral Arterial Disease progresses rapidly
JENA, Germany, May 24, 2021 /PRNewswire/ — Concept Medical Inc., focused on vascular intervention drug delivery devices, releases status updates of SIRONA Randomized Control Trial (RCT) which compares head-to-head, SIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in femoropopliteal arterial diseases (SIRONA). SIRONA is the world’s first RCT investigating the use […]